Pro-inflammatory innate-like T cells are expanded in the blood and inflamed intestine in Crohn’s Disease

ABSTRACT

A complex and tissue-specific network of cells including T lymphocytes maintains intestinal homeostasis. To address disease and tissue-specific alterations, we performed a T cell-centric mass cytometry analysis of peripheral and intestinal lymphocytes from patients with Crohn’s disease (CD) and healthy donor PBMCs. We compared inflamed and not inflamed tissue areas of bowel resections. Chronic inflammation enforced activation, exhaustion and terminal differentiation of CD4⁺ and CD8⁺ T cells and an enrichment of CD4⁺Foxp3⁺ cells (Tregs) in inflamed intestine. However, tissue-repairing Tregs decreased, while enigmatic rare Foxp3⁺ T-cell subsets appeared upon inflammation. In vitro assays revealed that those subsets, e.g. CD4⁺Foxp3⁺HLA-DR⁺TIGIT⁻ and CD4⁺Foxp3⁺CD56⁺, express pro-inflammatory IFN-γ. Some T-conventional (Tcon) cells tended towards innateness. In blood of CD patients, not well studied CD4⁺ and CD8⁺ subsets of CD16⁺CCR6⁺CD127⁺ T cells appeared anew, a phenotype reproducible by incubation of healthy blood T cells with patient blood plasma. Together, these findings suggest a bias towards innate-like pro-inflammatory Tregs and innate-like Tcon, which act with less specific cytotoxicity. Most likely, this is both cause and consequence of intestinal inflammation during CD.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was mainly supported by the Else Kroener-Fresenius Foundation 2015_A232. Additional funding was received by the Wilhelm Sander-Foundation/2012.047.2 (F.B.-S.), the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project number 324392634 - TRR 221 and FOR 2830 as well as the Fritz Thyssen Stiftung (Az. 10.13.2.215 and 10.17.2.012MN to F.B.-S.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was given by the ethical board of the University of Wuerzburg (proposal numbers 113/13, 46/11, 42/16), and all participants provided written, informed consent prior to participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes